Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit

被引：0
作者：
Adrien Joseph
Audrey Simonaggio
Annabelle Stoclin
Antoine Vieillard-Baron
Guillaume Geri
Stéphane Oudard
Jean-Marie Michot
Olivier Lambotte
Elie Azoulay
Virginie Lemiale
机构：
[1] U1138. INSERM,Metabolomics and Cell Biology Platforms
[2] Équipe 11 labellisée Ligue Nationale Contre Le Cancer,Service de Réanimation Médicale, Hôpital Saint
[3] « Metabolism,Louis
[4] Cancer & Immunity »,Service d’oncologie Médicale, Hôpital Européen Georges Pompidou
[5] Centre de Recherche Des Cordeliers,Service de Médecine Intensive Réanimation, Département Interdisciplinaire de L’Organisation Des Parcours Patient
[6] Gustave Roussy Cancer Campus,Service de Médecine Intensive Réanimation, Hôpital Ambroise Paré
[7] Assistance Publique Hôpitaux de Paris,INSERM UMR1018
[8] Assistance Publique Hôpitaux de Paris,Département D’innovations Thérapeutiques Et D’essais Précoces (DITEP)
[9] Université de Paris,Service de Médecine Interne Et D’immunologie Clinique
[10] Institut Gustave Roussy,Inserm, CEA, Centre de Recherche en Immunologie Des Infections Virales Et Des Maladies Auto
[11] Assistance Publique Hôpitaux de Paris,Immunes ImVA, UMR1184
[12] Team Kidney and Heart,U1153, INSERM, Équipe ECSTRA, Biostatistiques Et Épidémiologie Clinique
[13] CESP,undefined
[14] UFR des Sciences de la Santé Simone Veil,undefined
[15] Université Versailles Saint Quentin,undefined
[16] Faculté de médecine,undefined
[17] Université Paris Saclay,undefined
[18] Institut Gustave Roussy,undefined
[19] Hôpital Bicêtre,undefined
[20] Assistance Publique Hôpitaux de Paris,undefined
[21] Université Paris-Saclay,undefined
[22] Université de Paris,undefined
来源：
Annals of Intensive Care | / 10卷
关键词：
Cancer; Outcome; Adverse event; Immunotherapy; Intensive care; Immune-related adverse events; Immune checkpoint inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 239 条
  • [1] Hirsch L(2019)PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade Br J Cancer 120 3-5
  • [2] Zitvogel L(2019)Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance Nat Rev Clin Oncol 16 563-580
  • [3] Eggermont A(2017)Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer Chest 152 271-281
  • [4] Marabelle A(2017)Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy J Clin Oncol 35 709-717
  • [5] Martins F(2019)Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An Official American Thoracic Society Research Statement Am J Respir Crit Care Med. 200 e31-e43
  • [6] Sofiya L(2017)neurological complications associated with anti-programmed death 1 (PD-1) antibodies JAMA Neurol 74 1216-548
  • [7] Sykiotis GP(2019)Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors Nat Rev Clin Oncol 16 535-23
  • [8] Lamine F(1990)Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors Eur J Cancer Oxf Engl (1990) 2019 12-987
  • [9] Maillard M(2020)Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities Autoimmun Rev 19 102586-1916
  • [10] Fraga M(2018)Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents Liver Int 38 976-329
12345678910